This is Part 2 of Shared Decisions, Better Outcome: Collaboration in Managing Targeted Therapy for HR-Positive/HER2-Negative Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Erika Hamilton, MD, Melissa Rikal, MSN, FNP-BC, AOCNP®, and Heather Moore, CPP, PharmD, discuss multidisciplinary strategies for managing targeted therapy in hormone receptor-positive breast cancer. The patient is a 62-year-old woman with strongly ER/PR-positive, HER2-negative invasive lobular carcinoma who was initially treated with curative intent but later develops metastatic disease with diffuse bone involvement. She has a history of prior aromatase inhibitor intolerance and multiple comorbidities including prediabetes, anorexia, and opioid-related gastrointestinal symptoms.

 

The faculty emphasize proactive toxicity management, patient education, and frequent monitoring to improve adherence, underscoring how effective communication regarding potential side effects and dose reductions ensures long-term treatment success. The discussion highlights prophylactic strategies for key adverse events such as hyperglycemia, rash, diarrhea, and neutropenia, as well as the importance of multidisciplinary support.